Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades.

A 2012 study of patients with low-tumor-burden follicular lymphoma showed that the 4-year freedom from treatment failure rate ...

As a lymphoma survivor, I struggle with the positivity trap — sometimes, I just want my fears validated instead of being ...

Ensuring timely completion of post-approval studies and enforcing appropriate regulatory actions based on negative trial results is necessary to minimize patient exposure to ineffective and ...

Follicular lymphoma is a diverse disease, both biologically and clinically. Patients may present with indolent, asymptomatic disease or more aggressive, symptomatic disease with high tumor burden.

The FDA granted Crispr Therapeutics (CRSP) orphan status for its treatment of follicular lymphoma.Don't Miss Our End of Quarter Offers: ...

China’s National Medical Products Administration (NMPA) has granted conditional approval for Hutchmed’s Tazverik (tazemetostat) to treat adults with relapsed or refractory (R/R) follicular lymphoma ...

Axi-cel, tisa-cel, and brexu-cel were found comparable to other cellular therapy experiences for patients with B-cell ...

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.

TAZVERIK ® is a registered trademark of Epizyme Inc., an Ipsen company.